TAK-981-mediated inhibition of global SUMOylation spares skeletal muscle function
Authors:
- Mugeng LiMLMugeng Li
- Katharina BrandtKBKatharina Brandt
- Amel Nassar-GriouaANAmel Nassar-Grioua
- Luis Vincens GandLGLuis Vincens Gand
- Maja MilanovicMMMaja Milanovic
- Ulrich KellerUKUlrich Keller
- Theresia KraftTKTheresia Kraft
- Mamta Amrute-NayakMAMamta Amrute-Nayak
- Arnab NayakANArnab Nayak
Open Access
- 1 September 2026
- journal article
- Published by KEAI Publishing in Genes & Diseases
Abstract
No abstract availableFunding Information
- Deutsche Forschungsgemeinschaft
- Deutsche Krebshilfe
This publication has 5 references indexed in Scilit:
- Calcium Handling Machinery and Sarcomere Assembly are Impaired Through Multipronged Mechanisms in Cancer Cytokine‐Induced CachexiaJournal of Cachexia, Sarcopenia and Muscle, 2025
- Sorafenib induces cachexia by impeding transcriptional signaling of the SET1/MLL complex on muscle-specific genesiScience, 2024
- SUMOylation inhibitor TAK-981 (subasumstat) synergizes with 5-azacytidine in preclinical models of acute myeloid leukemiaHaematologica, 2023
- Discovery of TAK-981, a First-in-Class Inhibitor of SUMO-Activating Enzyme for the Treatment of CancerJournal of Medicinal Chemistry, 2021
- Chemotherapy triggers cachexia by deregulating synergetic function of histone‐modifying enzymesJournal of Cachexia, Sarcopenia and Muscle, 2020